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Abstract
A survey (via SurveyMonkey) was sent to lung cancer patients, their caregivers or significant others asking about their
experience in making difficult treatment decisions. Of the 198 respondents, 118 (69%) indicated that they had faced a
difficult decision with respect to their lung cancer treatment. Of those, 73% indicated that they would have desired that
the decision be made with their physician using a shared decision-making process, and 58% perceived that such a
process had occurred. In addition, only 23% of respondents indicated that they had had the right amount of information
when making the decision. Fortunately, only 9% of respondents expressed regret regarding the decision they ultimately
made. A Patient Decision Aid (PDA) was made available to the respondents to view, and opinions were sought
regarding the usefulness of this type of format for presenting information. This format was perceived as helpful, unsure
if helpful, or not helpful by 62%, 36%, and 2% of respondents, respectively. In summary, the majority of lung cancer
patients want to make difficult decisions using a shared decision-making process. The patient perception is that this is
not occurring often enough. Even in this fairly well-educated group of respondents, many report that they are not sure
that they have all the information necessary to make that difficult decision. Physicians may need help developing their
communication and shared decision-making skills. Introducing PDAs into the oncology clinic may represent a way to
present complex information and improve the patient experience.
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Introduction
Oncologists often ask lung cancer patients to make
important decisions regarding their treatment, often within
the setting of a single consultation. Patients are presented
with treatment options that are sometimes associated with
a significant degree of uncertainty as to their risks and
benefits. The Institute of Medicine expressed the opinion
that shared decision-making was necessary to produce the
best clinical outcomes possible.1 How oncologists present
information can be instrumental in what treatment
decision is made, the subsequent physician-patient
relationship, and the degree of regret experienced by the
patient should things not go as well as expected.
When one treatment option is not clearly superior to
another, Patient Decision Aids (PDAs) can help present
risks and benefits in a simple, visual format.2 A survey of
lung cancer patients or their significant others/caregivers
collected information regarding their decision-making
experiences, and their perceived usefulness of PDAs.)

A survey (via SurveyMonkey) was sent to lung cancer
patients, caregivers or significant others who had signed
up for email communication from the Bonnie Addario
Lung Cancer Foundation (ALCF), Global Resource for
Advancing Cancer Education (GRACE), or the University
of Colorado. Non-patient respondents were asked to
answer the survey, including the demographic information,
as they would have anticipated the patient would have
answered. In addition to the multiple choice format of
the SurveyMonkey questionnaire, all questions provided
the option to give freestyle comments. The survey process
and questions were approved by the Institutional Review
Board of the University of Colorado.
In order to seek opinions regarding the usefulness of
PDAs, a representative part of a PDA was shown (Figure
1). The figure provided was typical of how a PDA
presents the risks and benefits in a simple way, using
numerical and visual formats, combined with a very short
narrative.2 There was also a link to a full PDA for those
interested in seeing it.

Methods
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Figure 1. Survey question regarding the usefulness of a PDA

The survey was sent out in January 2016 and by September
2016, 198 completed surveys had been received.

to be white females. There were no Native American,
Alaskan Native, Native Hawaiian or Pacific islanders.

Results

Respondents were asked if they had faced a difficult
decision regarding their treatment. Sixty-nine percent of
the 198 respondents indicated that they had faced a
difficult decision. Women were more likely than men to
indicate that they had had a difficult decision to make
(83% vs 65%, p<0.05).

The demographics of the survey respondents are
summarized in Table 1. Given the distribution of the
survey through USA-based advocacy associations, it is not
surprising that the majority (83%) of respondents were
from the USA. The median age of respondents was 51-60
years old but all ages were represented. It was a relatively
well-educated group with 83% of respondents having
attended at least some college. Sixty-nine percent of the
respondents were married. Respondents were more likely
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The stage of lung cancer was Stage I or II (primary tumor
in lung without spread to mediastinal lymph or distant
organs, Stage III (primary tumor in lung with spread to
mediastinal lymph nodes without spread to distant organs),
Stage IV (metastatic to distant organs), or not known, in
15%, 14%, 56% and 15% of respondents, respectively.
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Table 1. Demographics of 198 survey respondents
Demographic variable
Respondent
Patient
Caregiver/support person
Country
United States
Canada
Other/No answer
Age (yrs)
< 30
31-40
41-50
51-60
61-70
71-80
> 81
No answer
Highest level of school completed
Elementary or middle school
High school or equivalent
Some college but no degree
Associate or bachelor degree
Graduate degree
No answer
Relationship status
Married
Widowed
Divorced
Single, never married
Other/No answer
Gender
Male
Female
No answer
Ethnic heritage
White
Black
Asian
Multi-cultural
No answer

N (%)
127 (64%)
71 (36%)
163 (83%)
15 (8%)
20 (9%)
4 (2%)
15 (8%)
30 (15%)
59 (30%)
54 (27%)
20 (10%)
4 (2%)
12 (6%)
2 (1%)
15 (8%)
26 (13%)
73 (37%)
68 (34%)
14 (7%)
137 (69%)
8
(4%)
18 (9%)
13 (8%)
22 (10%)
42 (21%)
128 (65%)
28 (14%)
150 (76%)
1 (.5%)
12 (6%)
4 (2%)
31 (10.5%)

The treatment situations associated with the difficult
decision are shown in Table 2. Under the “Other”
category respondents commented frequently on the
dilemma about joining a clinical trial, seeking a second
opinion, or changing treatment course due to toxicities.
When asked why the decision was difficult (again, more
than one answer was allowed), the most common answer
was that they felt they did not have enough information
(44%) or that they had heard conflicting information or
recommendations from their doctors (33%). Other cited
reasons were that they felt rushed to make the decision
(30%), heard conflicting information from non-medical
sources such as friends or internet (20%), disagreement
with significant other/support team (9%). Additional free
style comments alluded to practical issues (e.g., work,
expense, insurance, financial) with travelling for treatment
or for a second opinion, depression or feelings of futility
and helplessness, and difficulty dealing with the unknown.
Respondents used a variety of sources to help make the
decision although their physicians and the internet were
the most commonly cited sources (81% and 70%,
respectively). Table 3 summarizes these responses.
Respondents who indicated “Other” had varied comments
such as “relying on their gut feelings,” or indicated that
they used many of these sources and chose this response
as a default.
The amount of information available was categorized as
insufficient, just right, too much or difficult to know in
14%, 23%, 2%, 50%. Eleven percent preferred to answer
the question with explanations. Most of these comments
expressed confusion and uncertainty about the
information needed to make the “right” decision. Men
were more likely to indicate that they had “just the right
amount of information,” 39% vs 14%, p< 0.05.
Respondents were asked how “they would have liked to
make the decision” in terms of collaboration with their
physicians and family. The most common answer was that
they wanted their doctor(s) to make the decision jointly
with them (73%), with half indicating that they wished to
also have their family also involved in making the decision.
However, only 58% of respondents felt that their decision

Table 2. Treatment or situation associated with the difficult decision
Treatment modality or situation
Tests that were done or not done
Surgery
Radiation therapy
Chemotherapy (including targeted therapy)
End of life care
Other*
*See text
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% of respondents
34%
29%
29%
56%
12%
24%
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Table 3. Sources of information utilized by respondents (multiple sources allowed)
Source of information
Doctors
Internet
Books, pamphlets or other written material

Respondent number (%)
90 (81%)
78 (70%)
35 (31%)

Lung cancer patient advocacy groups or foundations
Friends or family
Other people with lung cancer (more informally than
patient advocacy group)
Nurses
Other
had been a shared decision with their doctors, with or
without their family’s input. Ten percent of respondents
indicated that the decision was primarily made by their
doctors. Unfortunately, 26% of respondents indicated that
they had made the decision by themselves. There was no
gender difference identified in the opinion regarding the
PDA, or regarding the wish for, or perception of, the
degree to which the decision was made jointly with their
doctors.
Respondents were asked if they regretted the decision that
they had made. Answers were given on a 5-point scale: 1
(strongly agree), 2 (agree), 3 (neither agree or disagree), 4
(disagree) or 5 (strongly disagree). Interestingly only 9%
of respondents expressed regret (answered 1 or 2)
regarding the decision that they had made. There was no
difference in this expression of regret between men and
woman. The following freestyle comments were offered
by respondents who expressed regret over the decision.
•
•
•

•
•
•

Regret that even the oncologist glossed over my
questions regarding (drug) sequencing
Not enough tissue obtained for more comprehensive
testing
I still wish my MD was more informative. I am
medical, intelligent and aware enough to handle the
tough realities. Just talk to me. I’m not in denial or
living in an illusion.
Not given some kind of follow-up PET scan postsurgery. Wonder if preventative chemo might have
eradicated the early activity.
I wish surgeon was more upfront about
complications. I got every complication imaginable.
Surgeon made it sound like piece of cake.
Whether to participate in a clinical trial or not.

Respondents were then shown a representative part of a
PDA (Figure 1) and asked if this type of decision aid
would have been helpful. Of the 91 respondents to this
question, 62% felt that a PDA would be helpful, and only
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51 (47%)
53 (47%)
28 (25%)
24 (21%)
30 (27%)
2% felt it would not be helpful. The remainder weren’t
sure or offered suggestions regarding modifying the PDA.
At the conclusion of the survey, respondents were given
the opportunity to make additional comments. Of the 40
additional comments, many indicated that they had faced
multiple difficult decisions throughout their illness. They
highlighted the complexity of making personal treatment
decisions based on the statistics available. Many were
appreciative of having the opportunity to answer the
survey, and hoped that further research into shared
decision-making would be forthcoming

Discussion
The importance of physicians and patients working
together to make decisions was highlighted in the Institute
of Medicine (IOM) report Crossing the Quality Chasm.1
This IOM report referred to patient-centered care as “care
that is respectful of and responsive to individual patient
preferences, needs, and values” and that ensures “that
patient values guide all clinical decisions.” The IOM
expressed the opinion that shared decision-making was
necessary to produce the best clinical outcomes possible.
Patients vary in their medical knowledge, but even a
patient who has done substantial research prior to the
consultation might have difficulty in applying that
information to his or her own situation. In addition,
patients vary in the extent to which they want to be
involved in the decision-making process.3 This was
apparent in our results in which approximately 75% of
patients wanted to be involved in making the difficult
decision.
Patient education materials are not meant to replace the
patient-physician consultation but to improve the decision
process. Often patients arrive at consultations or followup appointments not knowing the results of tests
indicating a need for a change in management, or there
may be an actual or perceived need to make a quick
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decision during that patient-physician interaction. Patients
often look to their health providers to point them to
appropriate education sources to support shared decisionmaking. However, even a patient who has done substantial
research prior to the consultation might have difficulty in
applying that information to his or her own situation. In
addition, patients vary in the extent to which they want to
be involved in the decision-making process.3
Another way in which oncologists can promote patientcentered care is by providing a written document
summarizing the treatment options discussed, and their
associated risks and benefits. Providing patients with a
visit summary has been designated as a quality indicator by
Medicare, part of the Meaningful Use criteria, by which
medical facilities can recoup some of their investment in
installing an electronic medical record (EMR).4 Other
techniques that have been shown to be effective include
the provision of pertinent published literature, tape
recordings of the interview, copies of the office notes, and
telephone calls before or after the visit. 5 Older lung cancer
patients may benefit from written materials that are
presented in a particular format. The Centers for Disease
Control and Prevention (CDC) has suggested guidelines
for oral and written questions with older adults or
caregivers
(http://www.cdc.gov/healthliteracy/developmaterials/aud
iences/olderadults. Accessed July 23, 2017).
Interestingly, patients are likely to be more satisfied with
the decision-making process if the physician
communicates the uncertainty associated with their
treatment recommendation.6 Clinicians need to relinquish
their role as the single, paternalistic authority and train to
become more effective coaches or partners. They have to
be comfortable asking, “What matters to you?” or “What
is the matter?”7
Another validated way of communicating the uncertainty
surrounding treatment options is the use of patient
decision aids (PDAs).8 PDAs can be used when there is
more than one reasonable option, when no option has a
clear advantage in terms of health outcomes, and when
each option has benefits and harms that patients may value
differently. PDAs may be in the form of written
information, videos, or web-based tools that make the
decision explicit, summarize the options available, and
help people to understand these options as well as their
possible benefits and harms.9 PDAs may contain real
patient antidotes in which one or the other decision was
made, with both good and bad outcomes. One expert
review concluded that effective PDAs present the risks
and benefits in numerical and visual formats, combined
with some narrative, and must take into account the ability
of the patient to understand the material2.
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The effectiveness of PDAs in cancer varies from tool to
tool, and there is controversy regarding the depth of
information that should be presented to the patient. 10-12
However, a Cochrane review regarding shared decisionmaking concluded that PDAs lead to significant changes in
the following variables.8
▪
▪
▪
▪
▪
▪

Increased patient knowledge
More accurate patient assessments of the
treatment risk
Lower decisional conflict related to feeling
uninformed
Reduced passivity in decision-making
Reduced number of undecided patients
Improved effect on patient-practitioner
communication

The Cochrane review also concluded that, on average, the
use of a PDA only increased the length of consultation by
approximately 3 minutes.
Of the 600 plus validated PDAs, less than 60 of these are
designed for cancer treatment decisions, and only 10 deal
with lung cancer diagnosis or treatment
(www.ohri.ca/decisionaid. Accessed July 20, 2017). These
can be accessed by patients and oncologists on the
internet. Clearly there is room for the development of
other lung cancer PDAs.
Unfortunately, the conclusions that can be drawn from
this survey are limited by the relatively homogeneous
population of respondents, primarily white Caucasian,
well-educated patients with access to the internet. A
future comparison of these results with other patient
populations would be extremely interesting.
In summary, lung cancer patients frequently face difficult
treatment decisions, and most, but not all, want to
participate in a shared decision-making process with their
doctor. However, the patient perception is that this is not
occurring as often as it could or should. Even in this fairly
well-educated group of respondents with access to many
educational resources, many report that they are not sure
that they had all the information necessary to make a
shared decision. Physicians may need encouragement and
education to develop their shared decision-making skills.
This could take the form of more open discussion to
explore the patient’s values and priorities, for example
asking the patient “what really matters to you?”.
Introducing more PDAs into the oncology clinic may
represent another way to present complex information and
enhance the shared decision-making process.
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